Financial Performance - The company's operating revenue for the third quarter was CNY 841.28 million, a decrease of 8.68% compared to the same period last year[5]. - Net profit attributable to shareholders was CNY 23.86 million, down 61.30% year-on-year[5]. - Basic earnings per share decreased by 60.00% to CNY 0.006 compared to the previous year[5]. - Net profit for the current period was CNY 20,933,355.19, down 72% from CNY 74,661,546.28 in the previous period[25]. - Earnings per share (EPS) for the current period was CNY 0.05, compared to CNY 0.18 in the previous period[25]. - The net profit for the first nine months of 2025 was significantly impacted by a 61.46% decrease in net cash flow from operating activities, totaling ¥18,870,338.04 compared to ¥48,958,629.78 in the same period of 2024[14]. Assets and Equity - Total assets as of September 30, 2025, were CNY 2,401,494,054.03, representing a decrease of 3.50% from the end of the previous year[10]. - The company's equity attributable to shareholders was CNY 2,259,307,721.16, down 2.18% from the end of the previous year[10]. - Total assets amounted to CNY 2,401,494,054.03, a slight decrease from CNY 2,488,655,694.01[22]. - Total equity attributable to shareholders was CNY 2,259,307,721.16, compared to CNY 2,309,688,533.16 in the previous period[22]. Cash Flow - The cash flow from operating activities was CNY 18.87 million, a decline of 61.46% compared to the same period last year[5]. - Operating cash inflow for the current period is CNY 313,930,607.85, a decrease from CNY 358,511,330.00 in the previous period, resulting in a net cash flow from operating activities of CNY 18,870,338.04, down from CNY 48,958,629.78[26]. - Cash inflow from investment activities totaled CNY 179,041,323.76, compared to CNY 88,261,830.31 in the previous period, with a net cash flow from investment activities of CNY 46,747,617.31, a significant improvement from a net outflow of CNY 1,085,211,025.10[26]. - Cash outflow from financing activities was CNY 72,815,730.94, down from CNY 138,240,000.00 in the previous period, leading to a net cash flow from financing activities of -CNY 72,815,730.94[27]. - The total cash and cash equivalents at the end of the period is CNY 535,821,483.35, slightly up from CNY 520,745,020.94 in the previous period[27]. Income and Expenses - Non-operating income for the period amounted to CNY 6,258,606.17, a decrease from CNY 20,389,536.01 in the previous year[8]. - The company reported a significant increase in prepayments, which rose by 61.54% to CNY 5,993,392.74 due to increased payments to suppliers[10]. - The company reported a financial expense of CNY -8,147,213.61, a significant improvement from CNY -44,105,422.65 in the previous period[24]. - The income tax expense decreased by 72.43%, amounting to ¥2,183,492.08, primarily due to a reduction in total profit[13]. - Total operating costs increased to CNY 318,613,218.65, up from CNY 263,843,342.98, reflecting a significant rise in operating expenses[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,918[16]. - The largest shareholder, Shanghai Yongda Sheng Business Consulting Co., Ltd., holds 38.25% of the shares, totaling 159,732,000 shares[16]. - The company issued 4.5 new shares for every 10 shares held, increasing the share capital to CNY 417.6 million, a 45.00% increase[12]. Other Information - The company did not report any other items that meet the definition of non-recurring gains and losses[9]. - The company has not yet adopted the new accounting standards effective from 2025[28]. - The third quarter financial report has not been audited[28].
亨迪药业(301211) - 2025 Q3 - 季度财报